Cargando…

PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation Dose

BACKGROUND: Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary rad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arora, Geetanjali, Shukla, Jaya, Ghosh, Sourabh, Maulik, Subir Kumar, Malhotra, Arun, Bandopadhyaya, Gurupad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307778/ https://www.ncbi.nlm.nih.gov/pubmed/22442740 http://dx.doi.org/10.1371/journal.pone.0034019

Ejemplares similares

Correction: PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation Dose
por: Arora, Geetanjali, et al.
Publicado: (2012)

(99m)Tc-DMSA (V) in Evaluation of Osteosarcoma: Comparative Studies with (18)F-FDG PET/CT in Detection of Primary and Malignant Lesions
por: Bandopadhyaya, G. P., et al.
Publicado: (2012)

Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
por: Levart, D., et al.
Publicado: (2019)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
por: Asbach, Stefan, et al.
Publicado: (2017)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
por: Starr, Jason S, et al.
Publicado: (2020)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

SUN-914 Peptide Receptor Radionuclide Therapy for an Inoperable Small Cell Neuroendocrine Tumor in the Philippines
por: Alegria, Rainier Mark Gabriel
Publicado: (2020)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
por: Liberini, Virginia, et al.
Publicado: (2020)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Opalińska, Marta, et al.
Publicado: (2021)

Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy
por: Hendifar, Andrew E., et al.
Publicado: (2022)

Radioactivity, radionuclides, radiation
por: Magill, Joseph, et al.
Publicado: (2005)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

Effect of Peptide Dose on Radiation Dosimetry for Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATOC: A Pilot Study
por: Prasad, Vikas, et al.
Publicado: (2021)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
por: Severi, Stefano, et al.
Publicado: (2017)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
por: Huizing, Daphne Merel Valerie, et al.
Publicado: (2018)

Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
por: Kipnis, Sarit T., et al.
Publicado: (2021)

Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases
por: Ngongoni, Rejoice, et al.
Publicado: (2022)

Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors
por: Hasegawa, Sho, et al.
Publicado: (2022)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

(225)Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
por: King, A. Paden, et al.
Publicado: (2023)

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo
por: Reuvers, Thom G.A., et al.
Publicado: (2023)

Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy
por: Khessib, Tasnim, et al.
Publicado: (2023)

Clinical Issues Related to Fluid Management during (177)Lu-Peptide Receptor Radionuclide Therapy in Metastatic Neuroendocrine Tumors with Carcinoid Heart Disease
por: Arora, Saurabh, et al.
Publicado: (2018)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
por: Sowa-Staszczak, Anna, et al.
Publicado: (2011)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
por: Purohit, Nupur K., et al.
Publicado: (2018)

Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
por: Braat, A. J. A. T., et al.
Publicado: (2019)

External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
por: Das, Satya, et al.
Publicado: (2022)

Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2022)

Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report
por: Kumar, Amit, et al.
Publicado: (2022)

Methods for assessing occupational radiation doses due to intakes of radionuclides
por: International Atomic Energy Agency. Vienna
Publicado: (2004)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6l7r14phk8gtsfmbflk4a88luk